Novo Nordisk Sends Prandin To Sciele As It Prepares For Liraglutide
Sciele Pharma's deal with Novo Nordisk to market Prandin (repaglinide) doubles the firm's presence in the diabetes treatment market
You may also be interested in...
With big pharma's bet on cannabinoid-1 receptor antagonists for obesity shadowed by the safety concerns behind the withdrawal of Sanofi-Aventis' Zimulti (rimonabant) NDA, the weight of late-stage development could fall on centrally acting drugs that act on extensively-studied neurotransmitters, primarily serotonin, and peripherally acting agents that promise an improved side effect profile
Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.
Despite voting that King's CorVu is not equivalent to its study comparator, Cardio-Renal panel sees bright future for the stress agent.